WO1999032486A1 - Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements - Google Patents

Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements Download PDF

Info

Publication number
WO1999032486A1
WO1999032486A1 PCT/US1998/027589 US9827589W WO9932486A1 WO 1999032486 A1 WO1999032486 A1 WO 1999032486A1 US 9827589 W US9827589 W US 9827589W WO 9932486 A1 WO9932486 A1 WO 9932486A1
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
pharmaceutically acceptable
chc
halogen
myopia
Prior art date
Application number
PCT/US1998/027589
Other languages
English (en)
Inventor
Bryon S. Severns
Mark R. Hellberg
Abdelmoula Namil
Hwang-Hsing Chen
Thomas R. Dean
Andrew Hoffman
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to AU23078/99A priority Critical patent/AU2307899A/en
Publication of WO1999032486A1 publication Critical patent/WO1999032486A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to new compounds having muscarinic activity.
  • the compounds are useful in treating glaucoma, myopia, various other medical conditions that directly or indirectly involve muscarinic receptors within the human body.
  • the invention is also directed to the treatment of glaucoma by controlling the principal symptom of that disease, elevated intraocular pressure. More specifically, the invention relates to the use of particular muscarinic compounds to control intraocular pressure ("IOP") and thereby prevent or at least forestall progressive field of vision loss and other manifestations of glaucoma.
  • IOP intraocular pressure
  • Glaucoma is a progressive disease which leads to optic nerve damage (i.e., glaucomatous optic neuropathy), and ultimately, partial or total loss of vision.
  • optic nerve damage i.e., glaucomatous optic neuropathy
  • the loss of visual field is secondary to the degeneration of optic nerve fibers which comprise the optic nerve.
  • the causes of this disease have been the subject of extensive studies for many years, but are still not fully understood.
  • IOP Intra major risk factor for glaucomatous optic neuropathy
  • the usual reason for elevated IOP is an impairment of the outflow of fluid (i.e., aqueous humor) from the eye.
  • aqueous humor a fluid that is not considered to be a common factor for elevated IOP
  • the pressure may be reduced by inhibiting the production (i.e., inflow, secretion or formation) of aqueous humor by the ciliary processes of the eye.
  • Beta adrenoceptor blockers and carbonic anhydrase inhibitors are examples of drug classes that lower intraocular pressure by inhibiting the inflow of aqueous humor.
  • Other classes of drugs reduce IOP by increasing the outflow of aqueous humor from the eye.
  • Examples of these drug classes include miotics, such as pilocarpine and carbachol, and adrenergics or sympathomimetics, such as epinephrine. While the use of the drug classes stated above is common practice in the medical therapy of glaucoma, it is not without side effects. Each class suffers from causing a particular set of side effects, locally and/or systemically, that is related to the pharmacological actions of that class. For example, beta blockers, by blocking beta adrenoceptors in the heart can cause bradycardia or slow heart rate, and by blocking beta adrenoceptors in the bronchi can cause bronchoconstriction.
  • miotics such as pilocarpine and carbachol
  • adrenergics or sympathomimetics such as epinephrine.
  • Muscarinic agents such as pilocarpine, may be used to reduce IOP by increasing the outflow of aqueous humor, but the use of these agents frequently produces side effects such as miosis, impaired accommodation and/or browache.
  • Miosis is caused by the contractile effect of the muscarinic agents on the iris sphincter. Muscarinic agents also have a contractile effect on the ciliary muscle. This effect is believed to be responsible for impairment of accommodation, as well as the browache experienced by some patients.
  • the agents used in glaucoma therapy show multiple pharmacological effects, some beneficial and some not. Since glaucoma medication must be taken over the patient's lifetime, it is advantageous to minimize the above-discussed side effects, so as to promote patients' compliance with the prescribed drug therapy, while maintaining the beneficial effect on intraocular pressure.
  • the compounds of this invention have minimal effects on pupil dilation and therefore offer an advantage over atropine or other compounds having muscarinic activity that have been suggested as therapeutics for myopia.
  • Studies of muscarinic receptors have shown that there are multiple subtypes of muscarinic receptors, and that these receptor subtypes may be localized in different tissues, or may otherwise mediate different pharmacological effects. While some non-selective muscarinic agents may interact with multiple receptors and cause multiple effects, other muscarinic agents may interact more selectively with one or a combination of muscarinic receptor subtypes such that the beneficial effects are increased while the detrimental side-effects are reduced.
  • PCT International Publication Number WO 97/16196 indicates that certain 1- [cycloalkylpiperidin-4-yl]-2H benzimidazolones are selective muscarinic agonists of the m2 subtype with low activity at the m3 subtype, and when utilized for glaucoma therapy have fewer side effects than pilocarpine therapy.
  • the present invention is based on the discovery of new muscarinic compounds and the use of these compounds to treat glaucoma, myopia and other medical conditions.
  • the following publications may be referred to for further background information regarding medical uses of compounds having at least some structure similarities to the compounds of the present invention:
  • PCT International Publication Number WO 97/24324 discloses 1-(1,2- disubstituted piperidinyl)-4-substituted piperidine derivatives as tachykinin receptor antagonists for treating pain;
  • PCT International Publication Number WO 97/16440 discloses 1-(1,2- disubstituted piperidinyl)-4-substituted piperazine derivatives as tachykinin receptor antagonists for treating pain;
  • PCT International Publication Number WO 97/16187 discloses 1,3-dihydro- l-[l-(l-heteroarylpiperazin-4-yl)cyclohex-4-yl]-2H-benzimidazol-ones as muscarinic antagonists for treating and/or preventing myopia;
  • United States Patent No. 5,574,044 discloses l,3-dihydro-l- ⁇ l-[piperidin-4- yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-ones and 1 ,3 -dihydro- 1 - ⁇ 4-amino- 1 -cyclohexyl ⁇ -2H- benzimidazol-2-ones as muscarinic antagonists for treating and/or preventing myopia; (5) United States Patent No.
  • 5,691,323 discloses l,3-dihydro-l- ⁇ l-[piperidin-4- yl]piperidin-4-yl ⁇ -2H-benzimidazol-2-ones and 1 ,3 -dihydro- 1 - ⁇ 4-amino- 1 -cyclohexyl ⁇ -2H- benzimidazol-2-ones as muscarinic antagonists for treating and/or preventing myopia;
  • United States Patent No. 5,718,912 discloses the use of 1- [cycloalkylpioeridin-4-yl]-2H benzimidazolones to treat glaucoma;
  • United States Patent No. 5,461,052 discloses the use of tricyclic compounds to prevent myopia
  • United States Patent No. 5,122,522 discloses the use of pirenzepine and other muscarinic antagonists in the treatment of myopia
  • United States Patent No. 5,637,604 discloses the use of muscarinic antagonists in the treatment and control of ocular development.
  • the present invention is directed to a new group of compounds and to the use of these compounds to treat various conditions that directly or indirectly involve muscarinic receptors.
  • the compounds may also be used to treat the symptoms of other types of conditions or injuries, based on the action of the compounds on muscarinic receptors. Examples of conditions that may be treated with the compounds of the present invention include glaucoma, myopia, dry eye and dry mouth (xerostoma).
  • the compounds may also be utilized to treat conditions of the central nervous system, such as psychosis and Alzheimer's disease.
  • the compounds have analgesic properties, and my therefore be used to treat various types of pain..
  • the compounds of the present invention are particularly useful in the treatment of glaucoma, based on the ability of the compounds to regulate intraocular pressure or
  • IOP insulin receptor
  • the compounds of the present invention are believed to control IOP via an action on muscarinic receptors. However, they are more potent than pilocarpine in lowering IOP, and, at a dose that causes an equal reduction in IOP, demonstrate a reduced level of miosis.
  • the production of miosis i.e., pupil constriction
  • the compounds of the present invention are also believed to be relatively free of the other major side effects associated with pilocarpine therapy, namely, impairment of accommodation and browache.
  • the compounds of the present invention have the following formula:
  • R is H, lower alkyl, alkoxyl, arylalkyl, alkynyl, alkenyl or cycloalkyl; D is CH or N;
  • R 1 and R 2 are independently H, lower alkyl, halogen, lower alkoxyl, OH, HOCH 2 , aryl, arylalkyl, SR or N(R) 2 ; and A is selected from the group consisting of:
  • R 3 is H, lower alkyl, halogen, lower alkoxyl, OH, HOCH 2 , aryl, arylalkyl, SR or N(R) 2 .
  • B is selected from the group consisting of:
  • R in CO 2 R does not equal H; and W is halogen, OR, R, N(R) 2 or SR, provided that when W is SR,
  • R does not equal H.
  • alkyl includes straight or branched chain aliphatic hydrocarbon groups that are saturated and have 1 to 15 carbon atoms (C, to C 15 ).
  • the alkyl groups may be substituted with other groups, such as halogen, hydroxyl or alkoxyl.
  • Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
  • cycloalkyl includes straight or branched chain, saturated or unsaturated aliphatic hydrocarbon groups which connect to form one or more rings, which can be fused or isolated.
  • the rings may be substituted with other groups, such as halogen, hydroxyl or lower alkyl.
  • Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cylopentyl and cyclohexyl.
  • alkenyl includes straight or branched chain hydrocarbon groups having 1 to
  • the chain hydrogens may be substituted with other groups, such as halogen.
  • Preferred straight or branched alkenyl groups include, allyl, 1-butenyl, l-methyl-2-propenyl and 4-pentenyl.
  • alkynyl includes straight or branched chain hydrocarbon groups having 1 to
  • the chain hydrogens may be substituted with other groups, such as halogen.
  • Preferred straight or branched alkynyl groups include, 2-propynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl and 2-pentynyl.
  • alkoxyl represents an alkyl group attached through an oxygen linkage.
  • lower alkyl represents alkyl groups containing 1 to 6 carbons (C, to C 6 ).
  • lower alkoxyl represents alkoxyl groups containing 1 to 6 carbons (C, to C 6 ).
  • halogen represents fluoro, chloro, bromo, or iodo.
  • aryl refers to carbon-based rings which are aromatic. Aromatic rings have alternating double and single bonds between an even number of atoms forming a system which is said to 'resonate'.
  • the rings may be isolated, such as phenyl, or fused, such as naphthyl.
  • the ring hydrogens may be substituted with other groups, such as lower alkyl, or halogen.
  • the most preferred compounds are those wherein m, n, o and p are 1 ;
  • R is lower alkyl, alkynyl or alkenyl.
  • salts of the compounds of formula (I) may also be utilized in the present invention.
  • examples of such salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate, or similar pharmaceutically acceptable inorganic or organic acid addition salts.
  • Compounds (5-7) may be prepared by combining the respective amines (1-3) with the appropriate ketone (4) and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride at a temperature of 20° C to 40° C and a pH in the range of 2-7.
  • a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride
  • the starting materials (5-7) and (4) are either commercially available or can be obtained by conventional procedures. The use of certain protecting groups and deprotecting steps may be necessary, as will be appreciated by those skilled in the art. Compounds of the formula (5-7) may exist as mixtures of stereoisomers. The preparation of individual stereoisomers may be effected by the chromatographic separation of the stereoisomers or by the selective control of the reaction conditions.
  • the 1,3,4-thiadiazole derivatives, 12 and 13 may prepared by the route outlined in
  • Compound (9) may be prepared by combining the protected cyclic diamine (8), with the appropriate ketone (4) and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride at a temperature of 20° C to 40° C and a pH in the range of 2 to 7.
  • the formamide protecting group may be removed by adding compound (9) to concentrated ammonium hydroxide and warming at reflux for 2 to 72 hours ("h") to provide the amine (10).
  • the formamide protecting group can be removed by stirring in a mixture of water and dioxane containing hydrochloric acid at a temperature of 0° C to 80° C for 1 to 72 h.
  • the 1,2,5-thiadiazole derivatives (lT)and (12) may be prepared by combining the appropriately substituted 3-chloro 1,2,5-thiadiazole derivative and the amine (10) in a solvent such as tefrahydrofuran, toluene or xylene and warming at a temperature of 40° C to 150° C for 1 h to 20 days.
  • Compounds of the formula (13) can be prepared by reacting the appropriate amine (HNR 2 ) with the chloro derivative (12) in a solvent such as tefrahydrofuran, dioxane, xylene, or neat warming at a temperature of 40° C to 150° C for 1 h to 20 days.
  • Compounds of the formula (15) may be prepared by combining the protected amino ester (14) with the appropriate ketone (4) and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride at a temperature of 20° C to 40° C and a pH in the range of 2-7.
  • the ester 15 can be converted to the heterocyclic derivatives represented by formula (16) by conventional procedures known to those experienced in the art.
  • the 1 ,2,4-oxadiazole derivative may be prepared by treating a solution of the ester (15) with a solution formed by reacting the appropriate amide oxime with a base such as sodium hydride in the presence of molecular sieves in a solvent such as tefrahydrofuran, dioxan or xylene at a temperature of 20° C to 100° C for 1 to 6 h.
  • a base such as sodium hydride
  • a solvent such as tefrahydrofuran, dioxan or xylene
  • the 1,2,4-thiadiazole derivatives may be prepared by reacting the ester (15) with a strong base such as lithium diisopropylamine in an inert solvent such as tefrahydrofuran at a temperature of -20° C to 50° C, for 0.5 to 2 h, followed by the addition of 5-chlorothiadiazole.
  • a strong base such as lithium diisopropylamine in an inert solvent such as tefrahydrofuran at a temperature of -20° C to 50° C, for 0.5 to 2 h
  • Ester hydrolysis and decarboxylation of the resulting product by sequential treatment with a base such as sodium hydroxide or lithium hydroxide followed by warming in an acidic solution (hydrochloric acid, trifiuoroacetic acid or sulfiiric acid) provides the 1, 2, 4- thiadiazole derivative.
  • the starting materials (8, 14) and (4) are either commercially available or can be obtained by conventional procedures. The use of certain protecting groups and deprotecting steps may be necessary, as will be appreciated by those skilled in the art. Compounds of the formula (11-13, 15, 16) may exist as mixtures of stereoisomers. The preparation of individual stereoisomers may be effected by the chromatographic separation of the stereoisomers or by the selective control of the reaction conditions.
  • the compounds of formula (I) are utilized to treat glaucoma, myopia and dry eye by topically applying a solution or other suitable ophthalmic composition containing the compound to the eye.
  • a solution or other suitable ophthalmic composition containing the compound to the eye.
  • the establishment of a specific dosage regimen for each individual patient is left to the discretion of clinicians.
  • the amount of the compound applied to the eye with each dose may vary, depending on the severity of the condition being treated, the drug release characteristics of the compositions in which the compound is contained, and various other factors familiar to those skilled in the art.
  • the amount of compound administered topically to the eye will generally be in the range of from about 0.3 to about 300 micrograms per dose, preferably from about 2 to about 100 micrograms per dose.
  • the compounds may be administered by topically applying one to two drops of a solution or comparable amount of a microemulsion, suspension, solid, or semi-solid dosage form to the affected eye(s) one to four times per day.
  • concentration of the compounds of formula (I) in such compositions will vary, depending on the type of composition utilized. For example, it may be possible to use a relatively lower concentration of the compound when compositions which provide for sustained release of the compounds or compositions which include a penetration enhancer are utilized.
  • the concentrations generally will be in the range of from about 0.001 to about 1 percent by weight, based on the total weight of the composition ("wt.%”), preferably from about 0.01 to about 0.3 wt.%.
  • the compounds of formula (I) may be included in various types of ophthalmic compositions. Since the compounds are relatively stable and soluble in water, the compositions will generally be aqueous in nature. Aqueous solutions are generally preferred, based on ease of formulation, as well as patients' ability to easily administer such compositions by means of instilling one to two drops of the solutions in the affected eyes. However, the compounds may also be readily incorporated into other types of aqueous compositions, such as viscous or semi- viscous gels or other types of solid or semi-solid compositions.
  • compositions of the present invention may also include one or more ancillary ingredients, such as preservatives, co-solvents and viscosity building agents.
  • Ophthalmic products are typically packaged in multidose form. Preservatives are thus required to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid, polyquaternium 1, or other agents known to those skilled in the art. Such preservatives are typically employed at a level of from 0.001% to 1.0% by weight.
  • a surfactant or other appropriate co-solvent may be included in the compositions.
  • co-solvents include: polyethoxylated castor oils, such as those manufactured by BASF under the Cremophor® brand; Polysorbate 20, 60 and 80; nonionic surfactants, such as the following Pluronic® brand surfactants of BASF: Pluronic® F-68, F-84 and P-103; cyclodextrin; or other agents known to those skilled in the art.
  • co-solvents are typically employed at a level of from 0.01% to 2% by weight.
  • Viscosity greater than that of simple aqueous solutions may be desirable to increase ocular absorption of the compound, to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the ophthalmic formulation.
  • Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art. Such agents are typically employed at a level of from 0.01% to 2% by weight.
  • An appropriate buffer system e.g., sodium phosphate or sodium acetate or sodium borate
  • sodium phosphate or sodium acetate or sodium borate may be added to prevent pH drift under storage conditions.
  • the compounds of formula (I) may also be utilized to treat psychosis, Alzheimer's disease, dry mouth, pain and various other conditions.
  • the compounds may be administered by any convenient method, for example, by oral, parenteral, buccal, rectal or transdermal administration.
  • the compounds may be administered via conventional pharmaceutical compositions adapted for such administration.
  • the compositions are generally provided in unit dose form (e.g., tablets), comprising 0.5 - 100 mg of one or more compounds of formula (I) in a pharmaceutically acceptable carrier, per each unit dose.
  • the dosage of the compounds is 1 - 300 mg/day, preferably 10 - 100 mg/day, when administered to patients, e.g. humans, as a drug.
  • the compounds may be administered one to four times a day.
  • compositions of the present invention further illustrates the topical ophthalmic pharmaceutical compositions of the present invention.
  • compositions of the present invention particularly oral tablet compositions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau groupe de composés présentant une activité muscarinique (I), m représentant 0 ou 1; p représentant 1 ou 2; X représentant C(R)2, O, S(O)3, NR, C(=O), CHOR, C=NOR, NC(=O)OR, NC(=O)N(R)2, NC(=O)R, CHC(=O)OR, CHC(=O)N(R)2, CHC(=O)R,NS(=O)2C(R)3; (a) ou (b); R1 et R2 représentant indépendamment H, alkyle inférieur, halogène, alkoxyle inférieur, OH, HOCH, aryle, arylalkyle, SR ou N(R)¿2?, et A étant choisi dans le groupe composé par (c), (d) et (e); ---- représentant une liaison simple ou double; n représentant 0 ou 1; o représentant 1 ou 2; R?3¿ représentant H, alkyle inférieur, halogène, alkoxyle inférieur, OH, MOCH¿2?, aryle, arylalkyle, SR ou N(R)2, et B étant choisi dans le groupe composé par (f), (g), (h), (i), (j), (k) et CO2R. L'invention concerne également l'utilisation de ces composés, et des sels pharmaceutiquement acceptables de ceux-ci, pour traiter le glaucome, la myopie, la psychose, et d'autres dysfonctionnement faisant intervenir des récepteurs muscariniques.
PCT/US1998/027589 1997-12-23 1998-12-22 Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements WO1999032486A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU23078/99A AU2307899A (en) 1997-12-23 1998-12-22 Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6856897P 1997-12-23 1997-12-23
US60/068,568 1997-12-23

Publications (1)

Publication Number Publication Date
WO1999032486A1 true WO1999032486A1 (fr) 1999-07-01

Family

ID=22083382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027589 WO1999032486A1 (fr) 1997-12-23 1998-12-22 Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements

Country Status (2)

Country Link
AU (1) AU2307899A (fr)
WO (1) WO1999032486A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020414A1 (fr) * 1998-10-02 2000-04-13 Combichem, Inc. Piperidyloxadiazoles utilises comme antagonistes durecepteur de la dopamine
WO2019243850A1 (fr) * 2018-06-22 2019-12-26 Heptares Therapeutics Limited Oxadiazoles à utiliser en tant qu'agonistes du récepteur muscarinique m1 et/ou m4
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists
US11999745B2 (en) 2020-12-18 2024-06-04 Heptares Therapeutics Limited Pharmaceutical compounds

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2724713A (en) * 1954-03-24 1955-11-22 American Cyanamid Co 1-carbobenzoxypiperazines and process of preparing same
EP0121972A2 (fr) * 1983-04-11 1984-10-17 Janssen Pharmaceutica N.V. N-aryl-alpha-aminocarboxamide
US4837241A (en) * 1986-09-08 1989-06-06 A/S Ferrosan Lipophillically-substituted piperidine oxadiazolyl compounds and their use in stimulating cognitive functions
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
US5328923A (en) * 1990-08-21 1994-07-12 Novo Nordisk A/S Heterocyclic compounds and use
WO1996026196A2 (fr) * 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines et piperazines utilisees comme antagonistes muscariniques
WO1997016440A1 (fr) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. Derives de piperazine a substitution en positions 1-(diperidinyle a disubstitution en positions 1,2)-4
WO1997024324A1 (fr) * 1995-12-27 1997-07-10 Janssen Pharmaceutica N.V. Derives 1-(piperidinyl 1,2-disubstitue)-4-substitue-piperidine comme antagonistes des recepteurs de la tachykinine
WO1997036899A1 (fr) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant
WO1997042956A1 (fr) * 1996-05-16 1997-11-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs emplois
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
DE19720011A1 (de) * 1997-05-14 1998-11-19 Boehringer Ingelheim Pharma Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Hetstellung

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2724713A (en) * 1954-03-24 1955-11-22 American Cyanamid Co 1-carbobenzoxypiperazines and process of preparing same
EP0121972A2 (fr) * 1983-04-11 1984-10-17 Janssen Pharmaceutica N.V. N-aryl-alpha-aminocarboxamide
US4837241A (en) * 1986-09-08 1989-06-06 A/S Ferrosan Lipophillically-substituted piperidine oxadiazolyl compounds and their use in stimulating cognitive functions
US5328923A (en) * 1990-08-21 1994-07-12 Novo Nordisk A/S Heterocyclic compounds and use
JPH0592921A (ja) * 1991-05-17 1993-04-16 Yamanouchi Pharmaceut Co Ltd シクロヘキシルアルキルアミド および 該化合物を有効成分とするタキキニン抑制剤
WO1996026196A2 (fr) * 1995-02-23 1996-08-29 Schering Corporation Benzylpiperidines et piperazines utilisees comme antagonistes muscariniques
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
WO1997016440A1 (fr) * 1995-10-30 1997-05-09 Janssen Pharmaceutica N.V. Derives de piperazine a substitution en positions 1-(diperidinyle a disubstitution en positions 1,2)-4
WO1997024324A1 (fr) * 1995-12-27 1997-07-10 Janssen Pharmaceutica N.V. Derives 1-(piperidinyl 1,2-disubstitue)-4-substitue-piperidine comme antagonistes des recepteurs de la tachykinine
WO1997036899A1 (fr) * 1996-03-30 1997-10-09 Boehringer Mannheim Gmbh Nouveaux derives de l'oxazolidine, leur procede de production et medicaments les contenant
WO1997042956A1 (fr) * 1996-05-16 1997-11-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines et leurs emplois
DE19720011A1 (de) * 1997-05-14 1998-11-19 Boehringer Ingelheim Pharma Abgewandelte Aminosäuren, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Hetstellung

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Neurotropic and psychotropic agents. CLXXXVI. Potential antitussives: synthesis and pharmacology of a series of 1-[2-amino-2-(4-fluorophenyl)ethyl]-4-(2-benzoylpropyl)piperazines", COLLECT. CZECH. CHEM. COMMUN., vol. 48, no. 10, 1983, pages 2977 - 2988, XP002101660 *
CHEMICAL ABSTRACTS, vol. 119, no. 13, 27 September 1993, Columbus, Ohio, US; abstract no. 139090y, MASE T ET AL: "Cyclohexylamides and tachykinin inhibitors containing the cyclohexylamides for pharmaceutical preparations." page 864; column 1; XP002101661 *
CHEMICAL ABSTRACTS, vol. 51, no. 13, 10 July 1957, Columbus, Ohio, US; NAZAROV I N ET AL: "Heterocyclic compounds. XLVI. Hydrolysis and alcoholysis of cyanohydrins of gamma-piperidones, tetrahydro-gamma-pyrones, and tetrahydro-gamma-thiopyrones. Synthesis of 1-alkyl-2,5-dimethyl-4-carbalkoxy-4-piperidols." column 9608h; XP002101662 *
MATTSON R J ET AL: "An improved method for reductive alkylation of amines using titanium(IV) isopropoxide and sodium cyanoborohydride", J. ORG. CHEM., vol. 55, no. 8, 1990, pages 2552 - 2554, XP002101659 *
ZHUR. OBSHCHEI KHIM., vol. 26, 1956, pages 3486 - 3500 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
WO2000020414A1 (fr) * 1998-10-02 2000-04-13 Combichem, Inc. Piperidyloxadiazoles utilises comme antagonistes durecepteur de la dopamine
US11793817B2 (en) 2011-11-18 2023-10-24 Heptares Therapeutics Limited Muscarinic M1 receptor agonists
US11834407B2 (en) 2016-10-14 2023-12-05 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
US10858352B2 (en) 2018-06-22 2020-12-08 Heptares Therapeutics Limited Pharmaceutical compounds
JP2021528447A (ja) * 2018-06-22 2021-10-21 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ ムスカリンｍ１および／またはｍ４受容体のアゴニストとしてのオキサジアゾール
US11319312B2 (en) 2018-06-22 2022-05-03 Heptares Therapeutics Limited Pharmaceutical compounds
US11773090B2 (en) 2018-06-22 2023-10-03 Heptares Therapeutics Limited Pharmaceutical compounds
CN112585135A (zh) * 2018-06-22 2021-03-30 赫普泰雅治疗有限公司 作为毒蕈碱m1和/或m4受体的激动剂的噁二唑
WO2019243850A1 (fr) * 2018-06-22 2019-12-26 Heptares Therapeutics Limited Oxadiazoles à utiliser en tant qu'agonistes du récepteur muscarinique m1 et/ou m4
US11945801B2 (en) 2018-12-07 2024-04-02 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5
US11999745B2 (en) 2020-12-18 2024-06-04 Heptares Therapeutics Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2307899A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
WO1999032481A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO1999032489A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
EP0738262B1 (fr) Nouveaux composes heterocycliques
EP0820451B1 (fr) Nouveaux composes heterocycliques
CN105412092B (zh) 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
CN1450896A (zh) 用吲哚衍生物降低眼内压的方法
US5756508A (en) Muscarine antagonists
US20090221642A1 (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US7279490B2 (en) Ophthalmic compositions for treating ocular hypertension
EA012668B1 (ru) Окулоселективные лекарственные средства и пролекарства
WO1999032479A1 (fr) Derives de phtalamidepiperidine, de phtalamidepyrrolidine, et de phtalamide-azepine, leur preparation, et leur utilisation comme agonistes(antagonistes) des recepteurs muscariniques
WO1999032486A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
EP2932968B1 (fr) Composé pour le traitement d'états à médiation alpha-adrénergique
WO1996031470A1 (fr) Nouveaux composes heterocycliques
US6166009A (en) N-substituted azaheterocyclic carboxylic acids and esters thereof
WO2009152053A1 (fr) Procédés de traitement d’affections à médiation alpha-adrénergique à l’aide de dérivés d’imidazoline
JPH0525167A (ja) 緑内障の治療に有用な置換ベンゼン誘導体
WO1999032443A1 (fr) Agents muscariniques et leur utilisation pour traiter le glaucome, la myopie, et d'autres dysfonctionnements
WO1999032445A1 (fr) Derives d'oximinopiperidine, d'oximinopyrrolidine, et d'oximinoazepine, leur preparation, et leur utilisation comme agonistes(antagonistes) des recepteurs muscariniques
EP0869954B1 (fr) Composes heterocycliques utiles dans le traitement d'une inflammation neurogenique
US6239148B1 (en) N-substituted azaheterocyclic carboxylic acids and esters thereof
WO1996031500A1 (fr) Composes heterocycliques nouveaux
EP0716657A1 (fr) $g(b)-CARBOLINES A SUBSTITUTION ALCOXY AGISSANT SUR LE RECEPTEUR D'AMPA
IE904155A1 (en) Novel heterocyclic carboxylic acids

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09582110

Country of ref document: US

122 Ep: pct application non-entry in european phase